{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:40:12Z","timestamp":1763545212446,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ygyno.2023.06.021","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T12:28:28Z","timestamp":1688560108000},"page":"16-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology\/gynecologic oncology group study 0283"],"prefix":"10.1016","volume":"176","author":[{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Soslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"DeLair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitriy","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea E.","family":"Wahner-Hendrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.06.021_bb0005","series-title":"Pathology and Epidemiology of Cancer","first-page":"233","article-title":"Epidemiology of ovarian and endometrial cancers","author":"Terry","year":"2017"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0015","doi-asserted-by":"crossref","first-page":"39088","DOI":"10.18632\/oncotarget.5142","article-title":"Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis","volume":"6","author":"Luchini","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10147-015-0811-x","article-title":"Loss of ARID1A expression is associated with poor prognosis in patients with stage I\/II clear cell carcinoma of the ovary","volume":"20","author":"Itamochi","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/path.4657","article-title":"Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma","volume":"238","author":"King","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0030","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-21-3817","article-title":"Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes","volume":"28","author":"Bolton","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2019.10.008","article-title":"Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival","volume":"155","author":"Alldredge","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0045","article-title":"Germline SMARCA4 deletion as a driver of uterine cancer: an atypical presentation","volume":"6","author":"Navitski","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0050","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1158\/0008-5472.CAN-11-1562","article-title":"ARID1A, a factor that promotes formation of SWI\/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers","volume":"71","author":"Guan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0055","article-title":"A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes","volume":"3","author":"Mortlock","year":"2022","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0060","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0070","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1097\/IGC.0b013e31826b5dcc","article-title":"Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma","volume":"22","author":"Ayhan","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/modpathol.2011.189","article-title":"Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations","volume":"25","author":"Yamamoto","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","article-title":"Vulnerabilities of mutant SWI\/SNF complexes in cancer","volume":"26","author":"Helming","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0085","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","article-title":"Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju146","article-title":"Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis","volume":"106","author":"Guan","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/cbt.28411","article-title":"The emerging roles of ARID1A in tumor suppression","volume":"15","author":"Wu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/modpathol.2011.161","article-title":"Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma","volume":"25","author":"Katagiri","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0105","first-page":"13","article-title":"Treatment strategies for ARID1A-deficient ovarian clear cell carcinoma","author":"Takahashi","year":"2021","journal-title":"Cancers (Basel)"},{"year":"2021","series-title":"Package Insert for Dasatanib (Sprycel)","key":"10.1016\/j.ygyno.2023.06.021_bb0110"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0115","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ygyno.2012.06.009","article-title":"Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"127","author":"Schilder","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0125","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-12-0507","article-title":"A phase I trial of dasatinib, an Src-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer","volume":"18","author":"Secord","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0135","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion - comment - rejoinder","volume":"16","author":"Brown","year":"2001","journal-title":"Stat. Sci."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0145","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.humpath.2014.08.007","article-title":"Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage","volume":"45","author":"Ye","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171356","article-title":"Yes1 signaling mediates the resistance to Trastuzumab\/Lap atinib in breast cancer","volume":"12","author":"Takeda","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0160","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.bmcl.2013.05.072","article-title":"Identification of potent Yes1 kinase inhibitors using a library screening approach","volume":"23","author":"Patel","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0165","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6605381","article-title":"Activity of the multikinase inhibitor dasatinib against ovarian cancer cells","volume":"101","author":"Konecny","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.06.021_bb0170","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-13-1854","article-title":"Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-yes\/YAP axis","volume":"20","author":"Touil","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00345-017-2143-0","article-title":"MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1","volume":"36","author":"Chen","year":"2018","journal-title":"World J. Urol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0180","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1158\/1078-0432.CCR-03-0589","article-title":"EphA2 expression is associated with aggressive features in ovarian carcinoma","volume":"10","author":"Thaker","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0185","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2023.05.006","article-title":"Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: a joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)","volume":"174","author":"Pothuri","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","article-title":"Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors","volume":"36","author":"Araujo","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0195","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1200\/JCO.2010.30.5474","article-title":"Phase II study of dasatinib in patients with advanced non-small-cell lung cancer","volume":"28","author":"Johnson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0200","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/JTO.0b013e3182161508","article-title":"Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib","volume":"6","author":"Johnson","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0205","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/cncr.29858","article-title":"SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma","volume":"122","author":"Schuetze","year":"2016","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2023.06.021_bb0215","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/neuonc\/nov011","article-title":"Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)","volume":"17","author":"Lassman","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"22\u201331","key":"10.1016\/j.ygyno.2023.06.021_bb0220","article-title":"A phase 2 trial of abiraterone followed by randomization to addition of dasatinib or sunitinib in men with metastatic castration-resistant prostate cancer","volume":"19","author":"Spetsieris","year":"2021","journal-title":"Clin. Genitourin Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:02:43Z","timestamp":1758772963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823003797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":44,"alternative-id":["S0090825823003797"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.06.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology\/gynecologic oncology group study 0283","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}